Spain Congress Publishes Sweeping Medicines And Health Products Bill

The Congress Bureau assigned the Government bill to the Health Commission with full legislative competence on 8 September. This is a parliamentary proposal, not an adopted law. Existing Spanish requirements and directly applicable European Union legislation remain in force, and the bill creates no new compliance obligation at publication.

Manufacturing, Supply And Product Scope

The proposal covers human and veterinary medicines, active substances, medical devices, in-vitro diagnostic medical devices, cosmetics and personal-care products. It also extends to substances, excipients and materials used to manufacture, prepare and package medicines, and to medical devices containing them.

Manufacturing and distribution provisions would retain authorisation, quality and good-practice controls while strengthening supply governance. The Spanish Agency of Medicines and Medical Devices would maintain public registers of pharmaceutical laboratories and manufacturers, importers or distributors of active substances. Registration would be required before active-substance activity begins, with immediate notification of quality, safety or efficacy-relevant changes and annual data updates.

The bill would formalise strategic medicines and permit regulatory, economic, financial or fiscal measures where shortage risks threaten availability. Marketing authorisation holders could be required to maintain shortage-prevention plans. During certain shortages, the Agency could direct supply through full-line pharmaceutical distributors. Pricing and public-financing provisions include dynamic pricing and possible upward reviews for designated strategic medicines.

Medical device, cosmetics and personal-care controls would sit within the same national inspection and sanctions architecture. The proposal does not itself introduce a new substance hazard classification, concentration limit or chemical exemption. Existing European Union product-specific limits and exemptions remain relevant.

Sanctions, Timing And Practical Implications

Proposed fines for serious infringements range from EUR30,001 to EUR90,000. Very serious infringements range from EUR90,001 to EUR1 million and may reach five times the value of the products or services concerned. These thresholds are proposed and cannot be enforced under the bill unless it becomes law.

If enacted in its current form, the law would enter into force 20 days after publication in the Official State Gazette. Administrative procedures already under way would continue under the rules applicable when they began. A sales-volume contribution provision has a separate transition to the first natural four-month period, beginning in January, May or September, after entry into force.

Manufacturers and importers should map proposed provisions against authorisations, active-substance records, shortage plans and product portfolios. Distributors should test continuity and traceability controls. Cosmetics and device businesses should review Spanish surveillance, import and sanctions exposure, while public-sector suppliers should monitor future procurement conditions, including environmental requirements for strategic medicines.

Analysis, clearly identified as an inference: the bill's largest operational effect may come from connecting functions that are often managed separately. Registration data, shortage forecasting, pricing, procurement and vigilance could become mutually dependent evidence streams. Businesses that assess only marketing authorisation changes may miss material supply-chain and enforcement exposure.

Related Foresight coverage examines Spain's proposed biocides framework, Spain's accessible-labelling requirements and the European Union's digital product-compliance reforms.